9 results on '"Conca R"'
Search Results
2. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab
- Author
-
Petrioli, Roberto, Licchetta, A, Roviello, Franco, Pascucci, A, Francini, E, Bargagli, G, Conca, R, Miano, St, Marzocca, G, Francini, Guido, Multidisciplinary Oncology Group on Gastrointestinal Tumors, and Savelli, Vinno
- Subjects
Oncology ,Male ,oxaliplatin-based chemotherapy ,Cancer Research ,endocrine system diseases ,Organoplatinum Compounds ,Colorectal cancer ,medicine.medical_treatment ,Angiogenesis Inhibitors ,Deoxycytidine ,CEA ,Stable Disease ,Antineoplastic Combined Chemotherapy Protocols ,Aged, 80 and over ,metastatic colorectal cancer ,bevacizumab ,CA 19-9 ,Tumor progression ,General Medicine ,Middle Aged ,Prognosis ,Bevacizumab ,Oxaliplatin ,Disease Progression ,CA19-9 ,Female ,Fluorouracil ,Colorectal Neoplasms ,medicine.drug ,Adult ,medicine.medical_specialty ,CA-19-9 Antigen ,Antineoplastic Agents ,Antibodies, Monoclonal, Humanized ,Capecitabine ,Internal medicine ,medicine ,Humans ,Aged ,Chemotherapy ,business.industry ,medicine.disease ,digestive system diseases ,Carcinoembryonic Antigen ,business ,Progressive disease - Abstract
We evaluated the changes of the tumor markers CEA and CA19.9 as early predictors of progression in metastatic colorectal cancer (mCRC) patients participating in a clinical study and receiving chemotherapy and bevacizumab (Bev). Seventy-two patients had high baseline CEA or CA19.9 serum levels. By ROC analyses, the areas under the curves were 0.83 for variable CEA cutoff values for distinguishing progressive disease (PD) versus stable disease (SD)/partial remission (PR)/complete remission (CR), and 0.80 for variable CA19.9 cutoff values for distinguishing PD versus SD/PR/CR. Rises in CEA and CA19.9 may early signal the occurrence of progression in mCRC patients receiving chemotherapy and Bev.
- Published
- 2012
3. Clinical features and genetic analysis of six patients with Wiskott-Aldrich syndrome reporting two novel mutations: Experience of Erciyes University, Kayseri, Turkey
- Author
-
Patiroglu, T., Klein, C., Gungor, H. Eke, Ozdemir, M. A., Witzel, M., Musa Karakukcu, Sawalle-Belohradsky, J., Conca, R., and Unal, E.
4. 14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three-year follow-up analysis
- Author
-
Ozawa, M., Terasaki, P. I., Castro, R., Alberu, J., Morales-Buenrostro, L., Alvarez, I., Toledo, R., Alvez, H., Monteiro, M., Teixeira, J., Campbell, P., Ciszek, M., Charron, D., Gautreau, C., Christiansen, F., Langan, L., Conca, R., Grosse-Wilde, H., Heinemann, F., Kamoun, M., Kobayashi, T., Kupatawintu, P., Lefor, W., Mehra, N., Panigrahi, A., Norman, D., ANTONINA PIAZZA, Poli, F., Roy, R., Schonemann, C., Lachmann, N., Sireci, G., Tanabe, K., Ishida, H., Den Berg-Loonen, E., and Zeevi, A.
- Subjects
Graft Rejection ,Histocompatibility Testing ,Graft Survival ,Histocompatibility Antigens Class I ,Kaplan-Meier Estimate ,Organ Transplantation ,Kidney Transplantation ,Education ,HLA Antigens ,Chronic Disease ,Heart Transplantation ,Humans ,Prospective Studies ,Follow-Up Studies ,Lung Transplantation - Abstract
The three-year follow-up of 4,144 patients of the 14th International Workshop Prospective Chronic Rejection study has reinforced the evidence that post-transplant HLA antibodies are predictive of long-term graft loss. Three years after a single testing for HLA antibodies, 10% of kidney recipients who were antibody-positive had lost their grafts, in contrast to only 5% of antibody-negative patients (p0.0001). The adverse effect of post-transplant antibodies on graft survival was also observed in lung, heart, and liver transplants. Donor-specific antibodies and 'strong' non-DSA had stronger association with graft loss than 'moderate' non-DSA. Periodic antibody monitoring, combined with specificity and strength analysis, would help in the early identification of allograft recipients who are at high risk of graft failure.
5. Therapeutic management of a symptomatic Kaposi’s sarcoma patient with renal failure undergoing haemodialysis: A case report
- Author
-
Anna Passarelli, Giovanna Galdo, Teresa Pellegrino, Giandomenico Roviello, Michele Aieta, Gabriella Aviello, Raffaele Conca, Passarelli, A., Galdo, G., Pellegrino, T., Roviello, G., Aieta, M., Aviello, G., and Conca, R.
- Subjects
Chronic renal impairment ,Pomalidomide ,Kaposi sarcoma ,Dermatology ,Human herpesvirus 8 ,Haemodialysi - Abstract
Kaposi’s sarcoma (KS) is a rare inflammation- based vascular cancer involving the skin. The viral aetiology of KS is the Human Herpesvirus 8. KS may be frequently diagnosed in immunosuppressed kidneytransplanted patients, while is less common in patients with dialysis. It is known that various immunological abnormalities can lead to impaired immune status in uremic patients. It is noteworthy that despite the incidence of KS in patients with renal impairment, only few cases have reported efficacy and safety profile of KS targeting anti-cancer drugs in this kidney disease population. Herein, we report the first case of a symptomatic KS patient with renal disease in haemodialysis and focus on its therapeutic management. We also review the main data available from literature regarding the safety of KS therapy in dialysis patients.
- Published
- 2021
6. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice
- Author
-
Oriana Commendatore, Milena Vitali, Raffaele Conca, Francesco Passiglia, and Passiglia F, Commendatore O, Vitali M, Conca R
- Subjects
0301 basic medicine ,Cancer Research ,Lung Neoplasms ,Settore MED/06 - Oncologia Medica ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,immune checkpoint inhibitor ,Disease ,NSCLC ,Bioinformatics ,B7-H1 Antigen ,immune checkpoint inhibitors ,Translational Research, Biomedical ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,PD-1 ,clinical studies ,PD-L1 ,biomarkers ,cancer immunogenicity ,translational research ,Molecular Targeted Therapy ,biology ,Immunogenicity ,General Medicine ,Oncology ,030220 oncology & carcinogenesis ,biomarker ,Cytokines ,Immunotherapy ,chemical and pharmacologic phenomena ,03 medical and health sciences ,Lymphocytes, Tumor-Infiltrating ,Immune system ,Biomarkers, Tumor ,medicine ,Humans ,Lung cancer ,business.industry ,Immunity ,Cancer ,medicine.disease ,030104 developmental biology ,Tumor Escape ,Mutation ,biology.protein ,business ,clinical studie - Abstract
Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to cancer immune evasion has allowed the development of a new class of drugs called immune checkpoint inhibitors, which reactivate host responses with outstanding clinical benefits in a portion of patients with non-small-cell lung cancer. In this review, we briefly summarize the basis of immunogenicity and immune escape of cancer, with specific focus on non-small-cell lung cancer, mechanisms underlying immune checkpoint inhibitors efficacy and the most updated results on potential biomarkers, with the final aim of defining current unmet needs of immunotherapy in clinical practice.
- Published
- 2018
7. Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer
- Author
-
Giandomenico Roviello, Michele Aieta, Pietro Rosellini, Raffaele Conca, Valerio Nardone, Roberto Petrioli, Andrea Giovanni Multari, Roviello, G, Petrioli, R, Nardone, V, Rosellini, P, Multari, A G, Conca, R, and Aieta, M
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Phases of clinical research ,docetaxel ,fluorouracil ,gastric cancer ,human epidermal receptor-2 ,oxaliplatin ,trastuzumab ,Administration, Intravenous ,Adult ,Antineoplastic Agents ,Antineoplastic Combined Chemotherapy Protocols ,Disease-Free Survival ,Docetaxel ,Esophagogastric Junction ,Female ,Humans ,Kaplan-Meier Estimate ,Male ,Neoplasm Staging ,Oxaliplatin ,Receptor, ErbB-2 ,Stomach ,Adenocarcinoma ,Fluorouracil ,Organoplatinum Compounds ,Stomach Neoplasms ,Taxoids ,Trastuzumab ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,In patient ,Receptor ,neoplasms ,business.industry ,Cancer ,General Medicine ,medicine.disease ,digestive system diseases ,Clinical trial ,030104 developmental biology ,030220 oncology & carcinogenesis ,business ,therapeutics ,medicine.drug - Abstract
The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal receptor-2 (HER-2) positive patients with advanced gastric or gastroesophageal junction (GEJ) cancer.Treatment consisted of docetaxel 70 mg/m combined with oxaliplatin 130 mg/m on day 1, and continuous infusion
- Published
- 2018
8. Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial
- Author
-
Giacomo Maria Guidelli, Maria Saveria Rotundo, Enrico Mini, Domenico Ciliberto, Maria T. Bianco, Antonella Licchetta, Elena Bestoso, Cirino Botta, Gabriella Misso, Ruggero Ridolfi, Pierpaolo Pastina, Michele Caraglia, Antonella Fioravanti, Annamaria Guglielmo, Luigi Pirtoli, Giovanni Mantovani, Pierfrancesco Tassone, Pierosandro Tagliaferri, Elodia Claudia Martino, Pierpaolo Correale, Maria Grazia Cusi, Raffaele Conca, Correale P., Botta C., Rotundo M.S., Guglielmo A., Conca R., Licchetta A., Pastina P., Bestoso E., Ciliberto D., Cusi M.G., Fioravanti A., Guidelli G.M., Bianco M.T., Misso G., Martino E., Caraglia M., Tassone P., Mini E., Mantovani G., Ridolfi R., Pirtoli L., Tagliaferri P., Correale, Pierpaolo, Botta, Cirino, Rotundo, Maria S., Guglielmo, Annamaria, Conca, Raffaele, Licchetta, Antonella, Pastina, Pierpaolo, Bestoso, Elena, Ciliberto, Domenico, Cusi, Maria G., Fioravanti, Antonella, Guidelli, Giacomo M., Bianco, Maria T., Misso, Gabriella, Martino, Elodia, Caraglia, Michele, Tassone, Pierfrancesco, Mini, Enrico, Mantovani, Giovanni, Ridolfi, Ruggero, Pirtoli, Luigi, and Tagliaferri, Pierosandro
- Subjects
Oncology ,Male ,Cancer Research ,Granulocyte-macrophage-colonystimulating- factor ,Organoplatinum Compounds ,medicine.medical_treatment ,Leucovorin ,Colorectal Neoplasm ,Gastroenterology ,Deoxycytidine ,FOLFOX ,Aldesleukin ,Phase iii trial ,Antineoplastic Combined Chemotherapy Protocols ,Immunology and Allergy ,Medicine ,Chemoimmunotherapy ,Neoplasm Metastasis ,Aged, 80 and over ,Middle Aged ,Neoplasm Metastasi ,Oxaliplatin ,Colorectal carcinoma ,Treatment Outcome ,Fluorouracil ,Female ,Colorectal Neoplasms ,Human ,medicine.drug ,Adult ,medicine.medical_specialty ,Immunology ,Lymphocytes, Tumor-Infiltrating ,Internal medicine ,Humans ,Aged ,Pharmacology ,Chemotherapy ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Organoplatinum Compound ,Granulocyte-Macrophage Colony-Stimulating Factor ,Gemcitabine ,Regimen ,Interleukin-2 ,Neoplasm Grading ,business - Abstract
The GOLFIG-2 phase III trial was designed to compare the immunobiological activity and antitumor efficacy of GOLFIG chemoimmunotherapy regimen with standard FOLFOX-4 chemotherapy in frontline treatment of metastatic colorectal cancer (mCRC) patients. This trial was conceived on the basis of previous evidence of antitumor and immunomodulating activity of the GOLFIG regimen in mCRC. GOLFIG-2 is a multicentric open/ label phase III trial (EUDRACT: 2005-003458-81). Chemo-naive mCRC patients were randomized in a 1:1 ratio to receive biweekly standard FOLFOX-4 or GOLFIG [gemcitabine (1000 mg/m 2, day 1); oxaliplatin (85 mg/m2, day 2); levofolinate (100 mg/m2, days 1-2), 5-fluorouracil (5-FU) (400 mg/m2 in bolus followed by 24 h infusion at 800 mg/m2,days 1-2), sc. GM-CSF (100 μg, days 3-7); sc. aldesleukin (0 ° 5 MIU bi-daily, days 8-14 and 17-30)] treatments. The study underwent early termination because of poor recruitment in the control arm. After a median follow-up of 43.83 months, GOLFIG regimen showed superiority over FOLFOX in terms of progression-free survival [median 9 ° 23 (95% confidence interval (CI), 6 ° 9-11.5) vs. median 5.70 (95% CI, 3.38-8.02) months; hazard ratio (HR): 0.52 (95% CI, 0.35-0.77), P=0 ° 002] and response rate [66.1% (95% CI, 0.41-0.73) vs. 37 °0% (95% CI, 0.28-0.59), P=0.002], with a trend to longer survival [median 21.63 (95% CI, 18.09-25.18) vs. 14.57mo (95% CI, 9.07-20.07); HR: 0 ° 79 (95% CI, 0.52-1.21); P=0.28]. Patients in the experimental arm showed higher incidence of non-neutropenic fever (18.5%), autoimmunity signs (18.5%), an increase in the number of monocytes, eosinophils, CD4+ T lymphocytes, natural killer cells, and a decrease in immunoregulatory (CD3+CD4 +CD25+ FoxP3+) T cells. Taken together, these findings provide proofof- principle that GOLFIG chemoimmunotherapy may represent a novel reliable option for first-line treatment of mCRC. Copyright © 2014 by Lippincott Williams & Wilkins.
- Published
- 2013
9. Plasma tryptophan levels and tryptophan/neutral amino acid ratios in obsessive-compulsive patients with and without depression
- Author
-
Valentina Lucini, Laura Bellodi, Adelio Lucca, Laura Bianchi, Stefano Erzegovesi, Roberta Conca, Bellodi, Laura, Erzegovesi, S, Bianchi, L, Lucini, V, Conca, R, and Lucca, A.
- Subjects
Adult ,Male ,Obsessive-Compulsive Disorder ,medicine.medical_specialty ,Fluvoxamine ,behavioral disciplines and activities ,chemistry.chemical_compound ,Internal medicine ,mental disorders ,medicine ,Humans ,Neurotransmitter ,Psychiatry ,Biological Psychiatry ,Depression (differential diagnoses) ,Retrospective Studies ,chemistry.chemical_classification ,Depressive Disorder ,Tryptophan ,Middle Aged ,medicine.disease ,humanities ,Amino acid ,Psychiatry and Mental health ,Endocrinology ,chemistry ,Major depressive disorder ,Female ,Serotonin ,Psychology ,Selective Serotonin Reuptake Inhibitors ,Anxiety disorder ,medicine.drug - Abstract
We have studied fasting plasma tryptophan (TRP) levels and tryptophan/large neutral amino acid (TRP/LNAA) ratios in 12 patients with obsessive-compulsive disorder (OCD) and 12 patients with OCD and a coexisting current diagnosis of major depressive disorder (OCD-MDD). Assessments were made at baseline and after 6 weeks of treatment with fluvoxamine. OCD-MDD patients had significantly lower baseline TRP levels and TRP/LNAA ratios than OCD patients. After 6 weeks of fluvoxamine treatment, OCD-MDD patients had significant increases in plasma TRP and TRP/LNAA ratio, whereas OCD patients had non-significant decreases. Our data suggest that a major depressive syndrome could be a state variable affecting the changes in plasma TRP and TRP/LNAA ratio in OCD patients. (C) 1997 Elsevier Science Ireland Ltd. Z8 0 ZR 0 ZS 0 ZB 8
- Published
- 1997
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.